All In Biotech

Drug Trial Radar · NCT03564964

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease

An Intermediate-Size, Expanded Access to SUVN-502 for the Treatment of Subjects With Alzheimer's Disease Who Have Completed the CTP2S1502HT6 Study

Last checked: Nov 20, 2026Latest source record: Sep 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

No longer available

Status

No longer available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Suven Life Sciences LimitedIndustry
Sponsor type
Industry
First posted
Jun 21, 2018

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 50 years, up to 85 years

Summary

As written by the sponsor on the registry.

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria. Subjects will not be evaluated for efficacy and safety during the expanded access.

Conditions

  • Alzheimer Disease
  • Dementia
  • Cognition Disorders

Interventions

  • SUVN-502Drug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.